Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
Clinical trial NCT06358430 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06358430
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-02
- Primary completion
- 2029-01-18
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.